A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

NCT07401875 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Phase 1b
HC-7366
SHARK
Kidney Cancer

Interventions

DRUG: Nivolumab
DRUG: HC-7366
DRUG: ipilimumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]